Stock info Swedish Orphan Biovitrum | Filter  Basic-Info

Swedish Orphan Biovitrum

The past year was a good year for Swedish Orphan Biovitrum investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Swedish Orphan Biovitrum, the stock lost around 19 percent. Over the period from December 2011 till December 2016 the stock rose on average 744 percent. Swedish Orphan Biovitrum's revenues between 2011 and 2015 were quite unstable and moved between 1,92 billion SEK and 3,23 billion SEK. Swedish Orphan Biovitrum's net incomes between 2011 and 2015 were quiet stable and moved between 68,98 million SEK and 68,39 million SEK.

Swedish Orphan Biovitrum's main office is based in Solna. The period from 2006 till the end of 2016 the international sector gained around 102 percent. As from 2011 the sector is 64 percent higher and over the past 12 months (December 2015-December 2016) there is a plus of 102 percent.

The Swedish company didn't pay out any dividends (in the past 5 years).

Swedish Orphan Biovitrum' balance mostly consists of equity

At the end of 2015 the Swedish company's balance sheet was worth 8,31 billion SEK. Of the total balance sheet 8,31 billion SEK (100 percent) was financed by debt. Last year the health care company's price/earnings-ratio (PE) was around 304. So the investors valued the stock at 304 times 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the Swedish stock can be seen as a growth stock.

The health care company's market capitalization (the number of shares outstanding times the market value) equaled around 35,36 billion SEK. At the end of 2015 the Swedish company had around 267,28 million stocks listed.

At this page you find all Swedish Orphan Biovitrum's financial reports. More information about Swedish Orphan Biovitrum can be found it's website. .